West Pharmaceutical Services, I vs ResMed Inc.
A head-to-head of West Pharmaceutical Services, I (WST) and ResMed Inc. (RMD) across valuation, profitability, growth, and dividends. Green marks the more favourable value on that metric only — not a recommendation.
| Metric | WST | RMD |
|---|---|---|
| Market Cap | $25.31B | $28.86B |
| P/E (TTM) | 47.79 | 19.19 |
| Forward P/E | 34.01 | 16.86 |
| P/S | 6.48 | 5.39 |
| P/B | 8.67 | 4.46 |
| EV/EBITDA | 24.06 | 13.65 |
| Dividend Yield | 0.24% | 1.17% |
| Profit Margin | 16.85% | 27.44% |
| Gross Margin | 35.89% | 59.36% |
| Operating Margin | 20.09% | 32.79% |
| Revenue Growth (YoY) | +21.01% | +10.81% |
| FCF Yield | 2.19% | 5.81% |
| Debt / Equity | 7.50 | 10.23 |
| Current Ratio | 2.71 | 3.01 |
Which is better: West Pharmaceutical Services, I or ResMed Inc.?
- ✓Larger by market cap: ResMed Inc.
- ✓Cheaper valuation (lower P/E): ResMed Inc.
- ✓Higher dividend yield: ResMed Inc.
- ✓More profitable (net margin): ResMed Inc.
- ✓Faster revenue growth: West Pharmaceutical Services, I
- ✓Higher free-cash-flow yield: ResMed Inc.
Across 13 available metrics, ResMed Inc. leads 11–2.
There's no single "better" — it depends on your goal: income investors may prefer the higher yield, growth investors the faster grower, and value investors the cheaper one. See each stock's page for deeper detail. This is an automated read, not a recommendation.
Share:
This comparison is for informational and educational purposes only, based on available data — not a recommendation to buy or sell any stock.